EGFR and non-small cell lung carcinoma: Therefore, from the perspective of the Chinese healthcare system, osimertinib is unlikely to be considered cost-effective for first-line treatment of advanced NSCLC with EGFR mutations relative to first-generation EGFR-TKI based on its current marketed price.